Summary

Eligibility
for people ages 22-80 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Kenneth J Chang, MD

Description

Summary

This single-blind randomized control study will follow 142 subjects across 5 sites randomized on a 1:1 ratio to compare treatment efficacy and safety between TIF and LNF in GERD patients with hiatal hernia undergoing hernia repair.

Official Title

MULTICENTER SINGLE-BLIND RANDOMIZED CONTROLLED TRIAL OF LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION FOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS REQUIRING HIATAL HERNIA REPAIR

Keywords

GERD Hiatal Hernia Hernia Hernia, Hiatal LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION Laparoscopic Nissen Fundoplication (LNF) Combo Transoral Incisionless Fundoplication (CTIF)

Eligibility

You can join if…

Open to people ages 22-80

  1. 22-80 years of age
  2. Subjects have GERD with hiatal hernia < 5 cm, and Hill grade III or IV
  3. Pathologic reflux while off PPI based on Lyon criteria by either of the following:

3.1. Conclusive evidence for pathologic reflux defined as acid exposure time (AET) > 6% or LA grade C or D esophagitis.

3.2. Borderline evidence of pathologic reflux defined as presence of one of the following parameters: AET 4-6%, LA grade A or B, and signed informed consent.

  1. Commitment to long-term study
  2. Ability to give consent individually or by a legally authorized representative

You CAN'T join if...

  1. Hiatal hernia > 5 cm
  2. Evidence of a major motility abnormality defined by the Chicago classification version 3.0 (achalasia, absent contractility, esophagogastric junction outflow obstruction, distal esophageal spasm, or hypertensive peristalsis)
  3. Pregnancy (in females) at time of procedure
  4. Previous anti-reflux procedure, have contraindications to the procedure will be excluded from participation.
  5. Subjects requiring mesh treatment at time of procedure
  6. Provider discretion
  7. BMI > 35

Locations

  • University of California Irvine not yet accepting patients
    Irvine California 92697 United States
  • University of Southern California not yet accepting patients
    Los Angeles California 90033 United States

Lead Scientist at UC Irvine

  • Kenneth J Chang, MD
    Clinical Professor, Medicine. Authored (or co-authored) 114 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Mayo Clinic
Links
Mayo Clinic Clinical Trials
ID
NCT04795934
Study Type
Interventional
Last Updated